AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Theranostic Approach for Pancreatic Cancer, 2019 - ResearchAndMarkets.com

November 25, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 25, 2019--

The “Theranostic Approach for Pancreatic Cancer” book from Elsevier Science and Technology has been added to ResearchAndMarkets.com’s offering.

Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.

Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.

Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer<- Discusses treatment options available currently and prospective options for the future- Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment

Key Topics Covered:

1. Biology, pathophysiology and epidemiology of pancreatic cancer

2. Diagnosis of pancreatic cancer

3. Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells

4. Drug resistance and microenvironment in pancreatic cancer

5. The role of tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy

6. Latest developments in chemotherapy for metastatic pancreatic cancer

7. Genetic manipulations with chemotherapy in pancreatic cancer

8. Genetic predisposition for pancreatic cancer

9. Pancreatic cancer resistance to chemotherapy: Resensitization strategies using resveratrol

10. Anti-cancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer

11. Targeting the epigenome as a therapeutic strategy for pancreatic tumors

Non-coding RNAs and chromatin remodelers

12. Pancreatic cancer chemoprevention: A review on molecular pathways involved in carcinogenesis and targeting with terpenoids, a new potential anti-tumor drugs

13. Meta-analysis on MTHFR polymorphisms and pancreatic cancer susceptibility

14. Therapeutic vaccines for pancreatic cancer

15. Epidermal growth factor receptor role in pancreatic cancer

16. Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer

Authors

For more information about this book visit https://www.researchandmarkets.com/r/rppcfq

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005442/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HOSPITALS PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/25/2019 08:02 AM/DISC: 11/25/2019 08:02 AM

http://www.businesswire.com/news/home/20191125005442/en